Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03866668
PHASE2

A Study of Esomeprazole in Children With Autism

Sponsor: Stanford University

View on ClinicalTrials.gov

Summary

Autism is a pervasive developmental disorder characterized by core deficits in social behavior and communication and the presence of repetitive/stereotyped behaviors. The objective of the study is to evaluate the efficacy of Esomeprazole as a treatment for social communication deficits in children with Autism Spectrum Disorder (ASD). This prospective 12 week open-label study will invite 25 children with ASD between the ages of 2 and 6 years of age to participate.

Official title: An Open-Label Pilot Study of Esomeprazole in Children With Autism

Key Details

Gender

All

Age Range

2 Years - 6 Years

Study Type

INTERVENTIONAL

Enrollment

25

Start Date

2019-05-29

Completion Date

2028-12

Last Updated

2025-11-12

Healthy Volunteers

No

Interventions

DRUG

Esomeprazole

Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks

Locations (1)

Stanford University School of Medicine

Stanford, California, United States